Comparison of suppressor and cytotoxic activity of blood mononuclears during adaptive immunotherapy of cancer patients with lymphokine-activated killer cells with a low dose of recombinant interleukin-2
Oncology
Received:
- 15 Downloads
Key Words
adaptive immunotherapy lymphokine-activated killer cells recombinant interleukin-2 cytotoxic lymphocytes and suppressorsPreview
Unable to display preview. Download preview PDF.
Literature Cited
- 1.I. F. Abronina, N. V. Malakhova, K. M. Figurin, et al., Byull. Éksp. Biol. Med., No. 9, 327 (1988).Google Scholar
- 2.I. F. Abronina and V. S. Anan'ev, Byull. Éksp. Biol. Med., No. 10, 473 (1988).Google Scholar
- 3.S. N. Bykovskaya, M. S. Iobadze, T. A. Kupriyanova, et al., Byull. Éksp. Biol. Med., No. 1, 86 (1987).Google Scholar
- 4.N. N. Trapeznikov, V. V. Yavorskii, A. B. Surkin, et al., Vestn. Vses. Onkol. Nauch. Tsent. Akad. Med. Nauk SSSR, No. 1, 31 (1990).Google Scholar
- 5.S. N. Bykovskaya, I. F. Abronina, T. A. Kupriyanova, et al., Biomed. Pharmacol.,44, 263 (1990).Google Scholar
- 6.M. Eura, T. Machara, T. Ikawa, et al., Cancer Immunol. Immunother.,27, 147 (1988).PubMedGoogle Scholar
- 7.B. Mukherji, S. A. Wilhelm, A. Guha, et al., J. Immunol.,136, 1888 (1986).PubMedGoogle Scholar
- 8.S. A. Rosenberg, M. T. Lotze, L. M. Muul, et al., New Engl. J. Med.,16, 889 (1987).Google Scholar
- 9.T. Tage, K. Kuroi, Y. Kininobu, et al., Clin. Exp. Immunol.,74, 409 (1988).PubMedGoogle Scholar
- 10.F. Vanky, A. Peterffy, K. Böök, et al., Cancer, Immunol. Immunother.,16, 17 (1983).Google Scholar
- 11.J. Wang, A. Wall, B. Gordon, et al., Am. J. Med.,83, 1016 (1987).PubMedGoogle Scholar
- 12.W. J. Urba, J. W. Clark, R. G. Steis, et al., J. Nat. Cancer Inst.,89, 602 (1989).Google Scholar
- 13.A. Yu, H. Watts, N. Jaffle, et al., New Engl. J. Med.,297, 121 (1977).PubMedGoogle Scholar
Copyright information
© Plenum Publishing Corporation 1992